Clinical trial
A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy…
NCT00411762 · Yale University, Other · Completed
Key facts
| NCT number | NCT00411762 |
|---|---|
| Title | A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma |
| Official title | A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma |
| Lead sponsor | Yale University, Other |
| Collaborators | PhytoCeutica Industry National Comprehensive Cancer Network Roche Pharma AG |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, PHY906 |
| Enrollment | 25 |
| Start date | Dec 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Dec 15, 2006 |
| Last update posted | Mar 27, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: